Drug news
NICE rejects Avastin/Xeloda (Roche) combination for Breast Cancer
NICE does not recommend the use of Avastin (bevacizumab) from Roche in combination with Xeloda (capecitabine) for first line treatment of metastatic Breast Cancer. It has previously refused to recommend Avastin in combination with a taxane for first line treatment. An improvement in overall survival and better quality of life was not clear.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.